Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer
21 oct. 2019 02h00 HE
|
Achilles Therapeutics
Achilles Therapeutics Appoints Beverley Carr as Chief Business OfficerBrings 20+ years of business development experience Formerly VP, Business Development for the Immuno-inflammation Therapy Area at...
Achilles Therapeutics raises £100 million in oversubscribed Series B financing
03 sept. 2019 07h00 HE
|
Achilles Therapeutics
Achilles Therapeutics raises £100 million in oversubscribed Series B financing - Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona- Confirms depth of...
Achilles Therapeutics raises £100 million in oversubscribed Series B financing
03 sept. 2019 02h00 HE
|
Achilles Therapeutics
Achilles Therapeutics raises £100 million in oversubscribed Series B financing - Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona- Confirms depth of...
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
13 févr. 2019 07h00 HE
|
Achilles Therapeutics
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
13 févr. 2019 03h00 HE
|
Achilles Therapeutics
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...
Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer
12 févr. 2019 07h00 HE
|
Achilles Therapeutics
Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer Stevenage, UK 12 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing...
Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer
12 févr. 2019 03h00 HE
|
Achilles Therapeutics
Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer Stevenage, UK 12 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing...
Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung Cancer
21 janv. 2019 07h00 HE
|
Achilles Therapeutics
Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung CancerGround-breaking clinical trial in patients with significant unmet medical need to start this year ...
Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung Cancer
21 janv. 2019 03h00 HE
|
Achilles Therapeutics
Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung CancerGround-breaking clinical trial in patients with significant unmet medical need to start this year ...
Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer
10 déc. 2018 07h00 HE
|
Achilles Therapeutics
Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer Stevenage, UK 10 December 2018 – Achilles Therapeutics (“Achilles” or...